Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) Net Margin (2017 - 2025)

Assembly Biosciences has reported Net Margin over the past 8 years, most recently at 52.01% for Q4 2025.

  • Quarterly results put Net Margin at 52.01% for Q4 2025, up 19249.0% from a year ago — trailing twelve months through Dec 2025 was 8.47% (up 13241.0% YoY), and the annual figure for FY2025 was 8.47%, up 13241.0%.
  • Net Margin for Q4 2025 was 52.01% at Assembly Biosciences, up from 85.23% in the prior quarter.
  • Over the last five years, Net Margin for ASMB hit a ceiling of 52.01% in Q4 2025 and a floor of 300.66% in Q3 2021.
  • Median Net Margin over the past 4 years was 135.57% (2024), compared with a mean of 125.5%.
  • Biggest five-year swings in Net Margin: tumbled -29098bps in 2021 and later soared 19249bps in 2025.
  • Assembly Biosciences' Net Margin stood at 300.66% in 2021, then surged by 49bps to 153.04% in 2023, then grew by 8bps to 140.48% in 2024, then soared by 137bps to 52.01% in 2025.
  • The last three reported values for Net Margin were 52.01% (Q4 2025), 85.23% (Q3 2025), and 105.94% (Q2 2025) per Business Quant data.